ArticleActa biomaterialia2018
A poly(beta-amino ester) activates macrophages independent of NF-κB signaling.
Article in Acta biomaterialia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Modeling lung adenocarcinoma using layer-by-layer nanoparticles mitigates innate immune cell activation.bioRxiv : the preprint server for biology · 2026Article
- Challenges and prospects of polymeric biomaterials in immune engineering: A review.Journal of biomaterials applications · 2026Review
- Poly(beta-amino esters): applications in immunology.Chemical science · 2026Review
- Biomimetic Polymer-Based Nanomaterials for Immune-Responsive Hepatocellular Carcinoma Therapy.International journal of nanomedicine · 2026Review
- In vitro study on the osteoimmunological potential of magnesium implants (WE43MEO).Biomedical engineering online · 2025Article
- Engineering immunity using metabolically active polymeric nanoparticles.Trends in biotechnology · 2025Review
- Nucleic acid-loaded poly(beta-aminoester) nanoparticles for cancer nano-immuno therapeutics: the good, the bad, and the future.Drug delivery and translational research · 2024Review
- A novel alternative for pyrogen detection based on a transgenic cell line.Signal transduction and targeted therapy · 2024Article
- mRNA Vaccine Nanoplatforms and Innate Immunity.Viruses · 2024Review
- Gastrointestinal Delivery of an mRNA Vaccine Using Immunostimulatory Polymeric Nanoparticles.The AAPS journal · 2023Article
- Harnessing Biomaterials to Study and Direct Antigen-Specific Immunotherapy.ACS applied bio materials · 2023Review
- Biomaterials-Mediated Engineering of the Immune System.Annual review of immunology · 2023Review
- Non-Modified CpG Oligodeoxynucleotide Forming Guanine-Quadruplex Structure Complexes with ε-Poly-Biomolecules · 2022Article
- Nanocarriers for pancreatic cancer imaging, treatments, and immunotherapies.Theranostics · 2022Review
- Advances in the polymeric delivery of nucleic acid vaccines.Theranostics · 2022Review
- Biomaterial nanocarrier-driven mechanisms to modulate anti-tumor immunity.Current opinion in biomedical engineering · 2021Article
- Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma.ACS applied materials & interfaces · 2021Article
- Self-Assembly as a Molecular Strategy to Improve Immunotherapy.Accounts of chemical research · 2020Article
- Poly(beta-amino ester)s as gene delivery vehicles: challenges and opportunities.Expert opinion on drug delivery · 2020Review
- Directing toll-like receptor signaling in macrophages to enhance tumor immunotherapy.Current opinion in biotechnology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Nucleic acid delivery vehicles are poised to play an important role in delivering gene therapy for vaccines and immunotherapies, and in delivering nucleic acid based adjuvants. A number of common polymeric delivery vehicles used in nucleic acid delivery have recently been shown to interact with immune cells and directly stimulate immunogenic responses, particularly in particle form. Poly(beta-amino esters) were designed for nucleic acid delivery and have demonstrated promising performance in a number of vaccine and therapeutic studies. Yet, little work has characterized the mechanisms by which these polymers activate immune cells. Here we demonstrate that a poly(beta-amino ester) activates antigen presenting cells in soluble and particulate forms, and that these effects are independent of TLR signaling pathways. Moreover, we show the polymers induce activation independent of NF-κB signaling, but do activate IRF, an important innate inflammatory pathway. New knowledge linking physicochemical features of poly(beta-amino esters) or other polymeric carriers to inflammatory mechanisms could support more rational design approaches for vaccines and immunotherapies harnessing these materials. SIGNIFICANCE STATEMENT: The last several years have brought exciting work exploring biomaterials as delivery vehicles for immunotherapies, vaccines, and gene therapies. However, a gap remains between the striking finding that many biomaterials exhibit intrinsic immunogenic features, and the specific structural properties that drive these responses. The results in the current study indicate PBAEs cause macrophage activation by pathways that are distinct from pathways activated by common vaccine and immunotherapies components, such as toll-like receptor agonists. Thus, the work reveals new mechanistic details that can be exploited in investigating other materials, and to support more rational design of future biomaterial vaccines and immunotherapy carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.